UK watchdog bans four weight loss pill ads that never named the drug

LONDON: Britain's advertising watchdog has banned four weight loss pill ads from three online providers, ruling that they promoted prescription only medicines to the public without naming them. The Advertising Standards Authority (ASA) ruled against two ads from Voy and one each from Juniper and MedExpress, according to The Independent and the pharmacy trade title Chemist and Druggist (C+D). The ASA said the ads were likely to be read as promoting oral Wegovy, the semaglutide tablet licensed in the UK in June. It is the second set of oral GLP 1 ad rulings in two months.

What the watchdog ruled against

Two of the banned ads came from a Voy campaign built on the line "The weight is over". One ran on the side of a bus in July and showed a hand holding a white tablet under that headline. The other was broadcast on video on demand services in August. It placed a pill next to the words "Oral weight support" and "It's kind of a small deal". Both ads carried smaller text about glucomannan, a food supplement. The ASA said the images and wording were likely to make people think of the newly available oral Wegovy tablets rather than a supplement. It said the small print did not change that impression. It added that the video ad also sent viewers to a website that listed prescription only weight loss medicines.

The other two weight loss pill ads did not name a medicine either. A YouTube ad for Juniper said "The weight loss pill is here" and, according to C+D, made claims about results and eligibility. An Instagram ad for MedExpress referred to "New weight loss tablets" and "No needles" and asked people to "Join the waitlist". The ASA said both ads promoted oral prescription only weight loss medicines without naming them directly. In each case the watchdog judged the ad as a whole rather than any single word or picture. The rulings deal with marketing. They make no finding about the safety or effect of the drug itself, and the reports did not say which complaints or checks first brought the four ads to the ASA's attention.

Why an unnamed pill still counts

The rulings turn on overall impression. The ASA said its own consumer research found that people read an ad as promoting a prescription only medicine from a mix of signals, including images, wording and references to weight loss. That means an ad can break the rules without naming a drug, the watchdog said. Catherine Drewett, investigations manager at the ASA, said the rulings show that advertisers "need to consider the overall impression their ads create". She said a small print reference to a non medicinal product "won't necessarily change that impression". The ASA said it uses AI monitoring and keeps the sector under ongoing review. Drewett said the watchdog "won't hesitate to take action against ads that break the rules".

That means an ad can break the rules without naming a drug, the watchdog said.

The Medicines and Healthcare products Regulatory Agency (MHRA) backed the decisions. Julian Beach, its executive director of operations, said the agency's advertising standards team works closely with the ASA and that it welcomed the rulings. "Prescription medicines are not consumer goods, and promoting them can have serious impacts on public health," Beach said. He said the safeguards exist to protect people and to support treatment decisions made between patients and their healthcare professionals. The Voy cases show how far that reasoning reaches. A picture of a white tablet beside a weight claim was enough for the ASA, even with a supplement named in the small print. For sellers of the new tablets, the message from both bodies is that the format of the medicine does not change the rule.

Prescription only medicine advertising in the UK

UK law bars the promotion of prescription only medicines to the public. A medicine must also hold MHRA authorisation before it can be advertised to the public at all, according to C+D's summary of the rules. Both rules shaped the ASA's oral GLP 1 cases. The MHRA authorised Novo Nordisk's Wegovy pill as a prescription only medicine on June 11, the first oral weight loss drug cleared in the UK. The tablet had been approved in the US in December 2025. The MHRA said the UK licence covers adults with a body mass index of 30 or above, and overweight adults with a BMI between 27 and 30 who have at least one weight related condition. The agency said the pill was not available on the NHS.

The latest rulings on weight loss pill ads follow a run of action by UK bodies. In June, the ASA, the MHRA and the General Pharmaceutical Council (GPhC) issued a joint warning to businesses advertising newly licensed weight loss drugs and those not yet licensed. Last month, the ASA banned oral weight loss drug ads for the first time. Those rulings covered Simple Online Pharmacy, whose ad was seen on June 1 before any oral GLP 1 had UK authorisation, and Pharmacy Online, which ran a website pop up inviting people to pre order the Wegovy pill after it was licensed. The ASA said the two had invited people to join waiting lists, register interest and pre order treatment. Separately, the GPhC issued Pharmacy Online with an improvement notice in August, C+D reported.

How the companies responded and what comes next

Voy chief medical officer Dr Earim Chaudry said patient decisions at Voy are led by clinicians and that the campaigns were developed to align with UK advertising standards, in a statement reported by The Independent. He said Voy withdrew the advertising while the investigation was under way and would not run it again. He added that the company cooperated fully with the ASA and acted promptly on its feedback. A MedExpress spokesperson said the ad had been flagged in a routine internal review before the ASA made contact and was then removed from all platforms. The spokesperson said the company would keep reviewing its marketing materials. Juniper did not respond to a request for comment from C+D, the trade title reported.

The ASA said its AI monitoring keeps the sector under review, so further rulings on weight loss pill ads are possible. What is not known is how many similar ads are still running, or whether any provider will face action beyond the rulings. For patients, the regulators' message is that the Wegovy pill is a prescription medicine, and the choice to use it belongs in a consultation with a healthcare professional. When the MHRA approved the tablet, National Pharmacy Association chair Olivier Picard warned that pills could be easier for criminals to counterfeit. He said patients should only obtain weight loss medication that is properly prescribed and dispensed by a regulated pharmacy. Any NHS use would follow a review by the National Institute for Health and Care Excellence, the MHRA said.

Conclusion

The ASA has now banned weight loss pill ads in two rounds since the Wegovy pill was licensed in June. Its test is the impression an ad gives, not whether it names the drug, and small print about a supplement did not save the Voy ads. The MHRA backed the rulings. The open questions are how many similar ads remain and whether enforcement goes further. New rulings will be tracked on our regulators desk.